HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$4.14
Day range
$4.01 - $4.18
Year range
$1.69 - $4.72
Market cap
758.90M USD
Avg Volume
1.17M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 1.73M | -62.89% |
Operating expense | 21.98M | -3.15% |
Net income | -19.80M | -15.81% |
Net profit margin | -1.15K | -212.06% |
Earnings per share | -0.15 | -14.22% |
EBITDA | -21.02M | -12.51% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 141.99M | -6.88% |
Total assets | 160.04M | -9.49% |
Total liabilities | 37.59M | -10.78% |
Total equity | 122.45M | — |
Shares outstanding | 188.78M | — |
Price to book | 6.37 | — |
Return on assets | -34.43% | — |
Return on capital | -42.30% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -19.80M | -15.81% |
Cash from operations | -14.50M | 25.84% |
Cash from investing | 9.83M | 582.10% |
Cash from financing | 24.37M | 413.92% |
Net change in cash | 19.69M | 247.17% |
Free cash flow | -7.10M | 31.18% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
73